Guidance
HPV vaccine lessons learnt project overview
Cervical cancer is a leading cause of morbidity and mortality among women in low- and middle-income countries, with nearly a half million new cases and 275,000 deaths annually. While screening programmes have helped reduce mortality rates in high-income countries, they are often unrealistic in low-income countries. In recent years, HPV vaccines, however, have emerged as an effective solution to prevent cervical cancer in low-resource settings, and the World Health Organization recommends HPV vaccination for girls aged 9 to 13 years.
Since 2007, low- and middle-income countries have gained experience in HPV vaccine delivery through HPV vaccination demonstration projects and national programmes. Dozens of countries have now gained valuable lessons about effective methods for garnering parental acceptance and reaching young adolescent girls with the vaccine, at relatively low delivery costs. This brief summarises the first comprehensive review of HPV vaccine delivery experiences across 37 low- and middle-income countries. The review was undertaken by researchers at the London School of Hygiene & Tropical Medicine and PATH from 2014 to 2015.
Authors
Languages
- English
Publication year
2015
Publisher
PATH
Type
Guidance
Categories
- Service delivery
Diseases
- HPV
Organisations
- PATH
Tags
- Coverage monitoring
- New vaccine introduction
- Performance monitoring
